

January 25, 2023

The BSE Limited

Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai – 400 001

Scrip Code: 541540

Dear Sir / Madam,

The National Stock Exchange of India Limited

Exchange Plaza, Bandra-Kurla Complex
Bandra (E), Mumbai – 400 051

Scrip Code: SOLARA

Subject: Outcome of Board Meeting – Intimation pursuant to Regulation 30 of Securities and Exchange - Board of India (Listing Obligation and Disclosure Requirements) Regulations, - 2015

Pursuant to Regulation 30 read with Part A, Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("**LODR Regulations**"), we wish to inform you that the Board of Directors of the Company has taken on record/approved the following changes in the Key Managerial Personnel (KMP) at its meeting held on January 25, 2023.

Name of the Director/KMP	Appointment
Mr Poorvank Purohit	Appointment as the Chief Executive Officer and as Key Managerial Personnel (KMP) of the Company.

Please note that the relevant details regarding the change in directors required to be disclosed under the SEBI circular CIR/CFD/CMD/4/2015 dated September 9, 2015, are enclosed herewith in the annexure to this letter. We request you to take the same on record.

Thanking you,
Yours faithfully,

For Solara Active Pharma Sciences Limited

S. Murali Krishna
Company Secretary

End: As above.

ANNEXURE

Name of the CEO	Mr Poorvank Purohit
Reason for change viz. appointment	<p>The position of CEO has been vacant since the exit of previous MD & CEO, Mr. Rajender Rao Juvvadi.</p> <p>The Board of Directors of the Company, pursuant to the recommendation by the Nomination and Remuneration Committee, has approved the appointment of Mr. Poorvank Purohit as Chief Executive Officer (CEO) of the Company.</p>
Date of appointment	This appointment is effective from 3 rd February, 2023
Brief Profile	<p>Mr Purohit hold a Bachelor in Chemical Engineering from M.S.Ramaiah Institute of Technology, Bangalore. He has also done Executive MBA from IIM Bangalore and completed Advance Management Program from Wharton School.</p> <p>He started his career as Management Trainee with Ranbaxy and progressed through various roles in leading pharma companies viz Hikel, Alembic, Jubilant Organosys - strong B2B experience in both APIs and Finished Dosage Forms.</p> <p>He is currently the Chief Operating Officer (COO) with R L Fine Chem Pvt Ltd, Bangalore.</p> <p>He has to his credit experience of turning round companies for exponential growth and sustainable organisation. His achievement includes building B2B businesses across geographies by establishing strong network and relationship with top Innovator/ Generic/ Dossier companies including CDMO companies.</p> <p>Holds a strong technical, commercial and management background.</p>
Disclosure of relationship between directors	Mr Purohit has no relationship with any of the directors of the company.